213 related articles for article (PubMed ID: 18543899)
21. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues.
Waser B; Tamma ML; Cescato R; Maecke HR; Reubi JC
J Nucl Med; 2009 Jun; 50(6):936-41. PubMed ID: 19443580
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin Receptor Antagonists for Imaging and Therapy.
Fani M; Nicolas GP; Wild D
J Nucl Med; 2017 Sep; 58(Suppl 2):61S-66S. PubMed ID: 28864614
[TBL] [Abstract][Full Text] [Related]
24. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
[TBL] [Abstract][Full Text] [Related]
25. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
[TBL] [Abstract][Full Text] [Related]
26. Biodistribution, Pharmacokinetics, and Dosimetry of
Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
[TBL] [Abstract][Full Text] [Related]
27. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
[TBL] [Abstract][Full Text] [Related]
28. Safety, Biodistribution, and Radiation Dosimetry of
Nicolas GP; Beykan S; Bouterfa H; Kaufmann J; Bauman A; Lassmann M; Reubi JC; Rivier JEF; Maecke HR; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):909-914. PubMed ID: 29025985
[TBL] [Abstract][Full Text] [Related]
29. Potent antagonists of somatostatin: synthesis and biology.
Hocart SJ; Jain R; Murphy WA; Taylor JE; Morgan B; Coy DH
J Med Chem; 1998 Mar; 41(7):1146-54. PubMed ID: 9544214
[TBL] [Abstract][Full Text] [Related]
30. N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo.
Schottelius M; Reubi JC; Eltschinger V; Schwaiger M; Wester HJ
J Med Chem; 2005 Apr; 48(8):2778-89. PubMed ID: 15828816
[TBL] [Abstract][Full Text] [Related]
31. Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model.
Waser B; Cescato R; Tamma ML; Maecke HR; Reubi JC
Eur J Pharmacol; 2010 Oct; 644(1-3):257-62. PubMed ID: 20643121
[TBL] [Abstract][Full Text] [Related]
32. De novo design, synthesis, and pharmacology of alpha-melanocyte stimulating hormone analogues derived from somatostatin by a hybrid approach.
Han G; Haskell-Luevano C; Kendall L; Bonner G; Hadley ME; Cone RD; Hruby VJ
J Med Chem; 2004 Mar; 47(6):1514-26. PubMed ID: 14998337
[TBL] [Abstract][Full Text] [Related]
33. Highly potent and subtype selective ligands derived by N-methyl scan of a somatostatin antagonist.
Rajeswaran WG; Hocart SJ; Murphy WA; Taylor JE; Coy DH
J Med Chem; 2001 Apr; 44(8):1305-11. PubMed ID: 11312929
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors.
Kazmierski W; Wire WS; Lui GK; Knapp RJ; Shook JE; Burks TF; Yamamura HI; Hruby VJ
J Med Chem; 1988 Nov; 31(11):2170-7. PubMed ID: 2903246
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs.
Cervia D; Nunn C; Fehlmann D; Langenegger D; Schuepbach E; Hoyer D
Br J Pharmacol; 2003 May; 139(1):109-21. PubMed ID: 12746229
[TBL] [Abstract][Full Text] [Related]
36. NOTA and NODAGA [
Makris G; Radford LL; Kuchuk M; Gallazzi F; Jurisson SS; Smith CJ; Hennkens HM
Bioconjug Chem; 2018 Dec; 29(12):4040-4049. PubMed ID: 30412382
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]